IGM Biosciences is restructuring its operations, which includes a reduction in workforce and is expected to incur restructuring charges between $11.7 million and $14.4 million, primarily for severance and stock-based compensation. The restructuring aims to minimize future spending on its oncology candidates and is expected to be completed by mid-2025.